High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration

23 October 2018

Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.

The OpACIN-Neo study, led by a team out of the Netherlands with a large number of patients recruited from Melanoma Institute Australia, showed a modified combination of the immunotherapies ipilimumab and nivolumab given prior to surgery produced a response in over 70% of patients. Importantly, there were drastically reduced side effects for patients and remarkably, none of these patients have relapsed to date.

Stage III patients are those whose melanoma has spread to their lymph nodes. Standard therapy for these patients is to undergo surgery to remove their melanoma, however those who undergo surgery alone have a significant risk (40-70%) of their disease recurring and progressing to Stage IV. Research in Stage IV melanoma patients demonstrates that combining ipilimumab and nivolumab is more effective than nivolumab alone, however this combination of drugs often causes extreme side effects for patients with many unable to continue treatment. Extrapolating from this data, the OpACIN-Neo study aimed to modify the dose of combined ipilimumab and nivolumab to reduce the incidence of toxicity while extending the efficacy seen in Stage IV patients to those with high-risk Stage III disease.

Previous research has shown that giving immunotherapy prior to surgery shrank the number of melanoma cells and increased long-term relapse-free survival. Neoadjuvant (pre-surgery) ipilimumab and nivolumab was also found to induce a stronger immune response, leading researchers to believe that when the immunotherapy is able to see the melanoma cells, they are able to assist the immune system to mount a more effective response.

In the OpACIN-Neo trial, researchers modified the standard dosing schedule by decreasing the dose of ipilimumab and increasing the dose of nivolumab and gave these prior to surgery. They found that after six weeks of therapy, the toxicity of the combination therapy was drastically reduced (only 20% of patients suffered a severe toxicity compared with those who received the standard dosing in that 6 weeks) while the efficacy was largely unchanged with a pathologic response seen in 77% of patients.

"These results are promising in that they provide an insight into the effects of altering the dosage and timing of giving combination immunotherapy to Stage III melanoma patients," said Co-Medical Director of Melanoma Institute Australia, Professor Georgina Long. "To have such a high level of response, coupled with greatly reduced toxicity for patients, means we are heading in the right direction with this vital area of immunotherapy research. The high rate of pathological response is exciting, as we know from a pilot study that those patients who had a pathological response haven’t had disease recurrence."

Stage III melanoma patients with bulky lymph node disease have the worst prognosis of Stage III patients, with 70-80% of them expected to recur within the first two years. After three years of follow-up in this pilot study, every patient who presented with a pathological response is yet to recur.

Promising results from a host of clinical trials investigating the use of neoadjuvant therapies in metastatic melanoma are being analysed by the International Neoadjuvant Melanoma Consortium, which also met at ESMO. This international group of researchers and clinicians aims to increase collaboration and standardise efforts in neoadjuvant treatment for melanoma. "This is one of the most exciting things happening in drug therapy in melanoma and has the capacity to ultimately change clinical practice around the world," Professor Long added.

Australian melanoma experts share latest breakthroughs with world's best oncologists
06 Jun 2018

Australian melanoma experts share latest breakthroughs with world's best oncologists

ASCO 2018 brings together the world's best in oncology from around the world. 

ASCO 2018 – the important role of clinical trials
06 Jun 2018

ASCO 2018 – the important role of clinical trials

Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.

MIA Scoops Awards at the International Academy of Pathology
04 Jun 2018

MIA Scoops Awards at the International Academy of Pathology

Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology. 

Updated Clinical Guidelines for Melanoma
25 May 2018

Updated Clinical Guidelines for Melanoma

Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.

Melanoma and Marital Status: A Study
11 May 2018

Melanoma and Marital Status: A Study

An American study has discovered a link between early detection and marital status in melanoma diagnosis. 

A weekend in Paris talking all things pathology...
02 May 2018

A weekend in Paris talking all things pathology...

An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.

Our own 'Australian Story'
30 Apr 2018

Our own 'Australian Story'

Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts. 

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
27 Apr 2018

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma

For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.

The inspiring story of Emma Betts premieres on Australian Story
16 Apr 2018

The inspiring story of Emma Betts premieres on Australian Story

'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma. 

Toyota helps tackle Australia's national cancer - melanoma
09 Apr 2018

Toyota helps tackle Australia's national cancer - melanoma

Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.

Tackling the Kokoda Trail for melanoma
06 Apr 2018

Tackling the Kokoda Trail for melanoma

Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.

Professor Richard Scolyer presents at world's largest annual meeting of pathologists
29 Mar 2018

Professor Richard Scolyer presents at world's largest annual meeting of pathologists

Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.

Congratulations to Kaye Oakley
29 Mar 2018

Congratulations to Kaye Oakley

A round of applause for a well deserved win.

Farewell from Carole Renouf, CEO of Melanoma Institute Australia
26 Mar 2018

Farewell from Carole Renouf, CEO of Melanoma Institute Australia

A message from our CEO, Carole Renouf

Marching in the twilight
26 Mar 2018

Marching in the twilight

Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma. 

Researchers uncover treatment sequence for advanced melanoma patients
23 Mar 2018

Researchers uncover treatment sequence for advanced melanoma patients

Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.

An unsung hero of melanoma care for nearly 30 years
22 Mar 2018

An unsung hero of melanoma care for nearly 30 years

Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.

Sharing our research on melanoma surgery
21 Mar 2018

Sharing our research on melanoma surgery

MIA is sharing it's research with the global surgical oncology community this week at the Society of Surgical Oncology Annual Cancer Symposium.

14 Melanoma Marches down, 7 to go!
19 Mar 2018

14 Melanoma Marches down, 7 to go!

It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.

Melanoma March keeps marching
14 Mar 2018

Melanoma March keeps marching

Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.